While AAV was originally used for "gene replacement" (adding a healthy gene), in late 2025 it is increasingly being used as the primary delivery vehicle for "in vivo" gene editing tools like CRISPR-Cas9. By packaging the "genetic scissors" inside an AAV vector, doctors can send the editing machinery directly to a patient's liver or eyes to "fix" a mutated gene in place. This "permanent repair" approach is more durable than traditional gene addition because it utilizes the body's natural genetic architecture. This convergence of AAV delivery and CRISPR editing represents the current "state-of-the-art" in genomic medicine.

According to the Adeno-associated Virus Vector-based Gene Therapy Sector, the segment for "Gene Editing Delivery" is a major driver of new clinical trials. In late 2025, several groundbreaking trials for hereditary blindness and metabolic disorders have reported successful "on-target" editing with minimal side effects. The challenge remains the "size limit" of the AAV capsid, which can only hold a relatively small amount of genetic material. Researchers are overcoming this by "splitting" the CRISPR machinery into two different AAV vectors that reassemble once they enter the target cell.

Moreover, the use of "base editing" and "prime editing" delivered via AAV is allowing for even more precise changes to the DNA without breaking the double strand. This "surgical" precision is reducing the risk of "off-target" mutations, which has been a primary safety concern for gene editing. As the year ends, the industry is seeing a shift toward "all-in-one" vectors that can deliver both the guide RNA and the editor protein in a single shell. The future of AAV is not just as a carrier of new genes, but as a delivery truck for the entire genetic toolkit.

Frequently Asked Questions

Q. Is AAV better than other viruses for delivering CRISPR? A. AAV is preferred because it does not cause disease in humans and is "non-integrating," meaning it delivers the editing tools and then eventually fades away once the job is done.

Q. What is the "size limit" of an AAV vector? A. AAV can carry about 4.7 kilobases of DNA; for larger gene-editing tools, scientists have to get creative by either using "mini-versions" of the tools or splitting them between two different viruses.